ML133 HCl: Unveiling Kir2.1 Channel Blockade in Vascular Remodeling Research

Introduction

Potassium channels, particularly those in the Kir2.1 subfamily, are pivotal regulators of membrane potential and cellular homeostasis in excitable and non-excitable cells. Recent advances in ion channel pharmacology have positioned ML133 HCl (B2199) as a transformative tool for dissecting the physiological and pathological roles of Kir2.1 in cardiovascular research. While previous articles have underscored ML133 HCl's selectivity and utility in disease modeling, this article delivers a comprehensive scientific deep dive, examining the molecular mechanism, experimental nuances, and translational frontiers that distinguish ML133 HCl in the landscape of potassium channel inhibitors.

Kir2.1 Potassium Channels and Their Role in Vascular Biology

The Physiological Importance of Kir2.1

The Kir2.1 potassium channel, encoded by the KCNJ2 gene, is a classical inwardly rectifying K⁺ channel that maintains resting membrane potential and supports potassium ion transport across cell membranes. In vascular smooth muscle cells—especially pulmonary artery smooth muscle cells (PASMCs)—Kir2.1 regulates excitability, contractility, and responses to vasoactive stimuli. Dysregulation of Kir2.1 activity has been implicated in pathological vascular remodeling, a hallmark of pulmonary hypertension (PH) and other cardiovascular disorders.

Kir2.1 in Pulmonary Artery Smooth Muscle Cell Proliferation and Migration

Hyperplasia and migration of PASMCs are central to the pathogenesis of PH, leading to increased pulmonary vascular resistance and adverse remodeling. Accumulating evidence reveals that Kir2.1 channels are upregulated during vascular remodeling, with downstream activation of proliferative and migratory signaling pathways. This mechanistic link positions Kir2.1 as a precise therapeutic and investigative target for pulmonary artery smooth muscle cell proliferation research and cardiovascular disease model development.

ML133 HCl: A Selective Kir2.1 Channel Blocker

Chemical Structure and Selectivity Profile

ML133 HCl, the hydrochloride salt of 1-(4-methoxyphenyl)-N-(naphthalen-1-ylmethyl)methanamine, is defined by its high selectivity for Kir2.1 channels. It exhibits an IC₅₀ of 1.8 μM at pH 7.4 and an even more potent 290 nM at pH 8.5, with negligible activity against Kir1.1 and only weak inhibition of Kir4.1 and Kir7.1. This pharmacological precision ensures targeted modulation of Kir2.1-mediated potassium ion transport while minimizing off-target effects—an essential attribute for high-fidelity cardiovascular ion channel research.

Physicochemical Properties and Handling

• Molecular Weight: 313.82 (C₁₉H₁₉NO·HCl)
• Solubility: Insoluble in water; soluble in DMSO (≥15.7 mg/mL) and ethanol (≥2.52 mg/mL) with gentle warming and ultrasonic treatment.
• Format & Storage: Supplied as a stable solid for storage at -20°C. Due to limited stability in solution, it is recommended to prepare fresh aliquots and avoid long-term storage post-dissolution.

Mechanistic Insights: ML133 HCl in PASMC Proliferation and Migration

While prior reviews have highlighted ML133 HCl's impact on PASMC behavior, this analysis draws directly from mechanistic findings in the recent seminal study by Cao et al. (2022). The researchers explored the effect of Kir2.1 inhibition on PASMC proliferation and migration, both in vivo (monocrotaline-induced PH rat models) and in vitro (human PASMCs exposed to PDGF-BB). Their work provides a blueprint for leveraging ML133 HCl to interrogate disease mechanisms with unprecedented specificity.

Experimental Highlights

• In Vivo: Monocrotaline-treated rats exhibited pronounced pulmonary vascular remodeling (PVR), with upregulated Kir2.1, OPN, and PCNA expression and activation of the TGF-β1/SMAD2/3 pathway in pulmonary tissues.
• In Vitro: Human PASMCs pre-treated with ML133 HCl showed reversal of PDGF-BB-induced proliferation and migration. ML133 HCl suppressed upregulation of OPN and PCNA and inhibited TGF-β1/SMAD2/3 signaling, directly linking Kir2.1 activity to the molecular circuitry of PASMC remodeling.

These results not only reinforce the centrality of Kir2.1 in vascular pathobiology but also establish ML133 HCl as a robust, causative probe for dissecting potassium channel-mediated signaling networks.

Comparative Analysis: ML133 HCl Versus Alternative Kir2.1 Modulators

Current literature—including the article 'ML133 HCl: Selective Kir2.1 Channel Blocker for Advanced ...'—has emphasized ML133 HCl’s benchmark specificity for cardiovascular ion channel research, contrasting it against non-selective potassium channel inhibitors and genetic knockdown approaches. Building upon these perspectives, this article delves deeper into:

• Temporal Control: ML133 HCl allows for acute, reversible inhibition of Kir2.1, facilitating dynamic studies of potassium channel function in live-cell and tissue models—an advantage over irreversible genetic modifications.
• Pharmacological Precision: The lack of significant off-target activity at effective concentrations ensures that observed phenotypes can be attributed with high confidence to Kir2.1 blockade.
• Versatility in Application: ML133 HCl’s solubility in DMSO and ethanol enables compatibility with a wide range of cell culture and ex vivo tissue protocols, supporting both basic and translational research needs.

Whereas the Compound56.com article streamlines experimental design and translational insights, this analysis focuses on the molecular mechanisms and nuanced experimental design considerations that optimize ML133 HCl’s use in advanced cardiovascular disease modeling.

Advanced Applications: ML133 HCl in Cardiovascular and Translational Research

Precision Modeling of Pulmonary Hypertension and Vascular Remodeling

By targeting Kir2.1, ML133 HCl enables the creation of highly controlled cardiovascular disease models that recapitulate key features of pulmonary hypertension and vascular remodeling. Its use facilitates:

• Dissection of Signaling Pathways: ML133 HCl-mediated inhibition of Kir2.1 allows researchers to probe the downstream involvement of TGF-β1/SMAD2/3, OPN, and PCNA—elucidating causal links between ion channel function and cellular phenotypes.
• Therapeutic Target Validation: Pharmacological blockade with ML133 HCl provides translationally relevant data for the validation of Kir2.1 as a therapeutic target in pulmonary and systemic vascular diseases.
• Vascular Smooth Muscle Cell Migration Assays: The compound’s acute reversibility makes it ideal for migration and wound healing assays, where temporal control is critical for parsing out dynamic cellular responses.

Expanding Beyond Pulmonary Hypertension: Broader Cardiovascular Contexts

While much attention has focused on PH, Kir2.1 channels have emerging roles in other cardiovascular contexts—such as atrial and ventricular arrhythmias, and systemic vascular disorders. ML133 HCl empowers researchers to extend their inquiry into these domains, leveraging its selectivity to parse out the contributions of Kir2.1 in complex tissue environments.

Technical Considerations for Experimental Success

• Solution Preparation: Ensure ML133 HCl is dissolved using DMSO or ethanol with gentle warming and ultrasonic treatment to achieve optimal solubility and experimental reproducibility.
• Stability: Prepare fresh solutions immediately before use and avoid repeated freeze-thaw cycles to maintain compound integrity.

Content Differentiation: Bridging Mechanistic Insight and Experimental Strategy

Unlike prior reviews that primarily discuss the value proposition and general applications of ML133 HCl (as seen in 'Redefining Pulmonary Vascular Research: Strategic Insight...'), this article uniquely synthesizes mechanistic findings with hands-on experimental guidance. We not only contextualize the compound within the broader landscape of potassium channel inhibitors but also provide actionable insights for researchers aiming to maximize impact in cardiovascular ion channel research. This approach bridges the gap between theoretical knowledge and practical application—a perspective not fully explored in the existing content ecosystem.

Conclusion and Future Outlook

ML133 HCl stands at the forefront of selective potassium channel inhibitors, offering unparalleled precision in the study of Kir2.1-mediated mechanisms of vascular remodeling. Its robust pharmacology, validated by mechanistic studies such as Cao et al. (2022), underscores its unique value for pulmonary artery smooth muscle cell proliferation research, vascular smooth muscle cell migration assays, and advanced cardiovascular disease models. As research advances, ML133 HCl will continue to catalyze new discoveries—not only in pulmonary hypertension but across the spectrum of cardiovascular biology.

For detailed product specifications and ordering information, see the ML133 HCl product page.